Gazelle Delivers Quantitative, Clinically Actionable Results at the Point of Care
The Gazelle diagnostic platform by Hemex Health detects and quantifies important blood-based conditions—from inherited disorders like sickle cell disease and beta thalassemia to iron-related and chronic conditions.
Gazelle quantifies critical blood biomarkers, delivering clinically actionable data—not just positive/negative answers.
Our device performs reliably in challenging environments and low-resource settings—yet meets the expectations of modern decentralized care settings.
Bringing diagnostics within reach.
Gazelle is changing lives in areas with limited access to testing
From our participation in India’s National Sickle Cell Anaemia Elimination Mission to testing newborns in the rural clinics of northern Ghana, Gazelle is helping to save lives. For communities with a high prevalence of sickle cell disease and other blood disorders, that have never had access to testing, Gazelle is making a difference.
Gazelle is available in over 40 countries
Since its introduction in 2021, Gazelle has been quickly adopted by health care providers in over 40 countries. Gazelle is sold through full-service medical distributors. This product is not cleared for sale in the United States.
Clinical Studies
Gazelle has participated in clinical studies throughout the world. Check out our many peer-reviewed publications, posters, and webinars.
Latest News
Press Release - February 6, 2026
Hemex Health Receives FDA Breakthrough Device Designation for Gazelle® Hb Variant Test
Hemex Health has received FDA Breakthrough Device Designation for its Gazelle® Hb Variant Test, recognizing its potential to address unmet needs in sickle cell disease monitoring. The designation enables prioritized engagement with the FDA as Hemex advances its point-of-care technology to deliver rapid, quantitative hemoglobin results closer to patients.
